Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) saw an erosion of -2.5 points in recent session. During the trading, the value of each share was $52, dropping -4.59%. The shares saw high fund-flow as the composite value of all the upticks was $13.8 million and the total value of all the downticks was a mere $11.83 million. The net money flow was seen at $1.97 million and the up/down ratio was measured at 1.17. On a weekly basis the shares of the shares have recorded a change of -5.44%.The block trade which occurred today had $2.08 million in upticks and $1.15 million in downticks with the up/down ratio climbing to 1.8. $0.93 million was the net money flow of the block transaction.
The stock has recorded a 20-day Moving Average of 21.27% and the 50-Day Moving Average is 21.68%. The company shares have dropped 47.45% in the past 52 Weeks. On July 20, 2015 The shares registered one year high of $137.05 and one year low was seen on February 9, 2016 at $49. The 50-day moving average is $64.51 and the 200 day moving average is recorded at $71.92. S&P 500 has rallied 1.93% during the last 52-weeks.
Ultragenyx Pharmaceutical (NASDAQ:RARE): The stock opened at $54.86 on Tuesday but the bulls could not build on the opening and the stock topped out at $54.86 for the day. The stock traded down to $51.14 during the day, due to lack of any buying support eventually closed down at $52.03 with a loss of -4.53% for the day. The stock had closed at $54.50 on the previous day. The total traded volume was 1,099,151 shares.
Currently the company Insiders own 10.1% of Ultragenyx Pharmaceutical shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -7.6% . Institutional Investors own 95.02% of Ultragenyx Pharmaceutical shares. During last six month period, the net percent change held by insiders has seen a change of -13.86%. On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the (Chief Medical Officer) of Ultragenyx Pharmaceutical Inc., Agarwal Sunil had sold 650 shares worth of $42,900 in a transaction dated May 24, 2016. In this transaction, 650 shares were sold at $66 per share.
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. Its products are KRN23 (UX023), rhGUS (UX003), rhPPCA (UX004), Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).